Paper Details

  1. Home
  2. Paper Details

Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762.

Author: Pavone-MacalusoM, SmithP H, SuciuS, de PauwM, de VoogtH J

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Diethylstilbestrol was associated with higher cardiovascular toxicity compared to other treatments. Fluid retention was the most common side effect. The risk of severe cardiovascular complications was highest during the first 6 months of treatment.
Paper Details　
Original Abstract of the Article :
Two randomized trials were started in 1976 by the European Organization for Research on Treatment of Cancer urological group. Trial 30761 compared 1 mg. diethylstilbestrol orally 3 times daily to 250 mg. oral cyproterone acetate daily and to 500 mg. medroxyprogesterone acetate intramuscularly 3 time...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0022-5347(17)45620-5

データ提供：米国国立医学図書館（NLM）

Cardiovascular Side Effects of Estrogen-Related Medications in Advanced Prostate Cancer

The treatment of advanced prostate cancer often involves estrogen-related medications, but these drugs can also have significant cardiovascular side effects. This study examines the cardiovascular toxicity of four estrogen-related medications: diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate, and estramustine phosphate, in patients with advanced prostate cancer. The researchers, like astute desert travelers assessing the risks of a particular route, sought to understand the potential cardiovascular risks associated with these medications, ensuring patients receive the best possible care.

The study reveals that diethylstilbestrol carries a higher risk of cardiovascular toxicity compared to the other three medications. This discovery provides valuable information for clinicians, helping them to make informed decisions about medication choices for patients with advanced prostate cancer. It's like choosing the most reliable camel for a long and arduous journey, ensuring the safest and most comfortable path for the traveler.

Navigating the Treatment Landscape: A Focus on Minimizing Cardiovascular Risk

This study highlights the importance of considering cardiovascular risks when treating patients with advanced prostate cancer. By understanding the potential side effects of different medications, clinicians can make informed decisions, choosing treatments that minimize the risk of cardiovascular complications. It's like carefully selecting a route through the desert, avoiding treacherous terrain and ensuring a safe and successful journey for the traveler.

Dr. Camel's Conclusion

This study provides valuable insights into the cardiovascular side effects of estrogen-related medications used in the treatment of advanced prostate cancer. By understanding these risks, clinicians can make informed treatment decisions, ensuring the well-being of their patients and guiding them towards a safer and more comfortable journey through treatment.

Date :
  1. Date Completed 1986-03-06
  2. Date Revised 2019-06-21
Further Info :

Pubmed ID

2935644

DOI: Digital Object Identifier

10.1016/s0022-5347(17)45620-5

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.